Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Clinical trial NCT06217757 · RECRUITING

Trial details

NCT number: NCT06217757
Sponsor: Sichuan University
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Lung Cancer Extensive-stage Small-cell Lung Cancer

Start date: 2024-04-18
Primary completion: 2027-10-31
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.